Skip to main content
OpenTrials
Completed

NCT Number: NCT02364180

Electromyography in Patients on Chronic Pyridostigmine Therapy

We intend to measure evoked EMG at two sites in subjects who are chronically taking pyridostigmine.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Muscle Weakness Muscular Diseases Musculoskeletal Diseases Nervous System Diseases Neurologic Manifestations Neuromuscular Manifestations Pathologic Processes Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

12 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Toledo, Health Science Campus

Toledo, Ohio, 43614, United States

About this study

The investigators are intending to enroll Patients who are chronically treated with pyridostigmine for the treatment of any medical condition and presenting at the investigators' outpatient clinics for follow up appointment. Subjects taking pyridostigmine for the treatment of myasthenia gravis will be excluded. Both adults and children older than 12 years of age will be approached. Those subjects that agree to participate will be asked to sign an informed consent. For the participation of minors a parental (or guardian) consent and subject assent will be obtained. Those that participate will answer a few questions pertaining to their medical history and will then undergo electromyograph (CMAP) measurement with repetitive stimulation at 2 sites (ulnar nerve at the wrist and the accessory nerve in the neck). Evoked electromyogram will be recorded on a computer hard drive. Eight percent or greater decrement in the CMAP response on repetitive stimulation will be considered positive.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects who have been taking pyridostigmine for the treatment of any condition other than myasthenia gravis

Exclusion criteria

  • Subjects taking pyridostigmine for the treatment of myasthenia gravis will be excluded.

Treatment and study plan

Electromyography (EMG)

Diagnostic Test

Primary outcomes

  1. Percent Change in the Amplitude of Evoked Compound Muscle Action Potential by Electromyography Between the First to Fifth Response

    Time frame: Baseline measurement only. First and Fifth stimuli delivered 2 seconds apart on the same day. There are no additional days/times.

    Normally when a nerve is rapidly stimulated the successive Compound Muscle Action Potentials (CMAP) are of the same height. We are hoping to investigate if chronic pyridostigmine therapy reduces the margin of safety and hence the successive CMAPs may be smaller than the preceding ones.

Sponsors and collaborators

Lead sponsor

University of Toledo Health Science Campus

Other

Registry information

Official study title

Electromyography With Repetitive Nerve Stimulation in Patients on Chronic Pyridostigmine Therapy

Important dates

Study start
2013
Primary completion
2016
Study completion
2016
First posted
Feb 16, 2015
Registry last updated
May 9, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.